Company: DVAX
Filing Date: 2025-04-17
Form Type: DEFC14A
Source: 0000930413-25-001273
Chunk: 99

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-17
Form: DEFC14A
Chunk 99
---
 for the
unique individuals they are. Our work related to these commitments focus on community outreach and engagement as well as efforts to support
leadership excellence and career development for all employees. As a vaccine company, bettering public health is core to our mission,
and that responsibility reaches to bettering the lives of our employees and broader communities.

Community Involvement and Philanthropy.In 2024, we continued
to partner with Life Science Cares, a non-profit organization that leverages the power of the life science industry to solve one of our
most intractable social issues—poverty. We also held our third annual Community Involvement Day in the U.S. in late 2024. During
this Community Involvement Day, all U.S. employees were encouraged to dedicate their day to volunteerism, and many employees volunteered
at local non-profits across the country. We also found several ways to support the Emeryville Unified School District with two scholarship
awards and guest speakers. We continue to provide all of our U.S. employees two paid days to volunteer in their local communities. Additionally,
from time to time, we make donations to support a variety of charitable organizations which we believe align with our core values.

Vaccine Access.We are
committed to developing and commercializing novel vaccines to help protect the world against infectious diseases, by
utilizing proven, innovative adjuvant technology. We are currently focused on our efforts to increase access and utilization
of our HEPLISAV-B vaccine through retail channels and integrated delivery networks, and we are advancing a pipeline of
differentiated product candidates that leverage our CpG 1018 adjuvant to develop improved vaccines in indications with unmet
medical needs. These programs include vaccine candidates under development for shingles and plague and additional vaccine
programs in preclinical development. We are currently conducting a randomized, active-controlled, dose escalation,
multicenter Phase 1/2 trial to evaluate the safety, tolerability, and immunogenicity of Z-1018 compared to Shingrix® in
441 healthy adults aged 50 to 69. We are also developing a plague (rF1V) vaccine candidate adjuvanted with CpG 1018® in
collaboration with, and fully funded by, the U.S. Department of Defense (“DoD”).

Additionally, we manufacture and have supplied in the past CpG 1018
adjuvant, the adjuvant used in HEPLISAV-B